Neuromyelitis optica spectrum disorder natural history, complications and prognosis
Jump to navigation
Jump to search
|
Neuromyelitis optica spectrum disorder Microchapters |
|
Differentiating Neuromyelitis optica spectrum disorder from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Neuromyelitis optica spectrum disorder natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Neuromyelitis optica spectrum disorder natural history, complications and prognosis |
|
FDA on Neuromyelitis optica spectrum disorder natural history, complications and prognosis |
|
CDC on Neuromyelitis optica spectrum disorder natural history, complications and prognosis |
|
Neuromyelitis optica spectrum disorder natural history, complications and prognosis in the news |
|
Blogs on Neuromyelitis optica spectrum disorder natural history, complications and prognosis |
|
Directions to Hospitals Treating Neuromyelitis optica spectrum disorder |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Julinka Auta Fernandes
Overview
- Neuromyelitis optica spectrum disorder (NMOSD) usually follows a relapsing course characterized by acute attacks of optic neuritis, myelitis, area postrema syndrome, or other brainstem, diencephalic, or cerebral syndromes. In aquaporin-4 immunoglobulin G (AQP4-IgG)-positive NMOSD, the risk of relapse persists indefinitely; a monophasic course should therefore be assigned with great caution.[1][2]
- Disability in NMOSD is acquired predominantly during attacks because recovery may be incomplete. A single severe attack may cause permanent blindness, major motor disability, or respiratory insufficiency; repeated attacks can produce cumulative neurologic disability.[2][3]
- Sustained clinical worsening independent of attacks is uncommon, although subtle relapse-independent retinal or central nervous system injury has been reported. A 2026 decade-long cohort found progression independent of relapse activity (PIRA) in 2.5% of patients with AQP4-IgG-positive NMOSD.[2][4]
- Common long-term complications include visual loss, paresis and impaired mobility, sensory loss, neuropathic pain, spasticity, bladder, bowel, and sexual dysfunction, fatigue, depression, and reduced quality of life. Mortality has declined substantially with earlier recognition and modern care, but severe brainstem or high cervical spinal-cord attacks and urosepsis remain potentially fatal.[2]
Natural History
- Neuromyelitis optica spectrum disorder has an attack-related natural history. The clinical course can be understood as an index attack, variable recovery, and—particularly in AQP4-IgG-positive disease—recurrent attacks separated by periods of relative clinical stability.[1][2]
| Phase or feature | Expected course |
|---|---|
| Index attack | NMOSD may begin with optic neuritis, acute myelitis, area postrema syndrome, an acute brainstem syndrome, a symptomatic diencephalic syndrome, or a symptomatic cerebral syndrome. Attack severity ranges from mild sensory or visual symptoms to blindness, tetraparesis, or respiratory insufficiency.[2] |
| Evolution of one attack | Manifestations affecting the optic nerve, spinal cord, brainstem, or cerebrum may emerge successively during the same attack. The Neuromyelitis Optica Study Group (NEMOS) considers new symptoms arising within 4 weeks of attack onset part of the same attack; an event beginning more than 4 weeks after the initial attack may be classified as a new attack after exclusion of alternative explanations.[2] |
| Recovery | Recovery is variable and may be incomplete. Residual visual, motor, sensory, autonomic, pain, or bulbar deficits may remain after the first attack; even one severe attack can cause permanent disability.[2][5] |
| Relapse | Virtually all patients with AQP4-IgG-positive NMOSD should be regarded as having persistent relapse risk, particularly without effective relapse prevention. The interval between the first and second attacks is highly variable—from approximately 1 month to more than a decade; a large European cohort cited by NEMOS reported a median interval of 9 months.[2] |
| Interattack course | Neurologic status is usually stable between attacks. Clinically meaningful PIRA is rare, but subtle relapse-independent structural or functional injury can occur; therefore, absence of overt attacks does not necessarily imply absence of all biologic disease activity.[2][4] |
| Long-term course | Cumulative disability is driven mainly by the number, location, severity, and recovery of attacks. A long remission does not eliminate future relapse risk in AQP4-IgG-positive disease.[2][6] |
Course according to antibody status
- Neuromyelitis optica spectrum disorder has different natural-history implications according to antibody status.[2]
| Group | Interpretation |
|---|---|
| AQP4-IgG-positive NMOSD | A relapsing course is expected, and relapse risk should be considered lifelong. Apparent long-term remission must not be assumed to represent cure or a permanently monophasic course.[2] |
| AQP4-IgG-negative and myelin oligodendrocyte glycoprotein immunoglobulin G-negative NMOSD | The group is heterogeneous and may include relapsing or monophasic disease. A monophasic designation requires prolonged observation and continuing reassessment for alternative diagnoses.[1][2] |
| Myelin oligodendrocyte glycoprotein immunoglobulin G-positive disease | Patients who fulfill the criteria for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) should be classified as MOGAD rather than NMOSD because its natural history and prognosis are distinct.[2] |
Pregnancy-associated course
- Neuromyelitis optica spectrum disorder may become more active during the postpartum period and possibly during the third trimester. Positive AQP4-IgG status, younger age, disease activity before pregnancy, and interruption of relapse-prevention therapy are associated with greater pregnancy or postpartum attack risk.[3]
- Active NMOSD has been associated with increased risks of spontaneous abortion and eclampsia. These are population-level associations and do not determine the outcome of an individual pregnancy.[3]
Complications
- Neuromyelitis optica spectrum disorder may cause acute complications during an attack and chronic sequelae from incomplete neurologic recovery.[2]
| Domain | Complications and sequelae |
|---|---|
| Visual | Persistent reduction in visual acuity, impaired color vision or visual fields, optic atrophy, severe visual disability, or blindness after optic neuritis. Sequential involvement of the fellow eye may result in bilateral visual impairment.[2] |
| Motor and mobility | Persistent paraparesis or tetraparesis, gait impairment, falls, dependence on walking aids or a wheelchair, and loss of independence after myelitis.[2][7] |
| Sensory, pain, and tone | Sensory loss, dysesthesia, allodynia, neuropathic pruritus, neuropathic pain, painful tonic spasms, and spasticity-associated pain. Chronic pain is common and may substantially impair quality of life.[2][8] |
| Autonomic and pelvic-organ dysfunction | Neurogenic bladder, urinary retention or incontinence, recurrent urinary tract infection, urosepsis, bowel dysfunction, constipation or fecal incontinence, and sexual dysfunction after spinal-cord injury.[2][7] |
| Bulbar and respiratory | Dysphagia, dysarthria, aspiration, aspiration pneumonia, sleep-related breathing impairment, or respiratory failure from medullary or high cervical spinal-cord involvement. Respiratory insufficiency is a recognized cause of NMOSD-related death.[2] |
| Area postrema and metabolic | Prolonged nausea, vomiting, or hiccups may lead to dehydration, weight loss, malnutrition, acute kidney injury, or electrolyte disturbance.[2] |
| Diencephalic and cerebral | Hypersomnolence or narcolepsy, syndrome of inappropriate antidiuretic hormone secretion, cognitive impairment, headache, and—rarely—epileptic seizures.[2] |
| Neuropsychological and social | Fatigue, depression, anxiety, cognitive difficulties, loss of employment or independence, caregiver burden, and reduced quality of life. Pain and depression are important independent contributors to impaired quality of life.[2][8][7] |
| Secondary effects of severe disability | Immobility may increase the risk of pressure injury, deconditioning, contractures, osteoporosis, falls, and venous thromboembolism; bladder dysfunction may predispose to recurrent infection and urosepsis.[2][7] |
Prognosis
- The prognosis of neuromyelitis optica spectrum disorder is variable. Untreated or inadequately controlled relapsing disease may lead to severe visual, motor, autonomic, and respiratory disability; outcomes have improved with earlier diagnosis, prompt attack care, and effective relapse prevention.[2][3]
- Historical estimates of blindness, paralysis, and mortality should not be applied directly to contemporary patients because diagnostic definitions, supportive care, and relapse-prevention strategies have changed substantially. No single universal 5-year or 10-year survival estimate is valid across all NMOSD populations.[2]
Prognostic factors
| Factor | Prognostic association |
|---|---|
| Attack severity and recovery | A severe index attack, poor recovery, and severe subsequent attacks are associated with greater permanent disability. Even one attack may produce a major irreversible deficit.[2][5] |
| Number and type of attacks | Recurrent attacks drive cumulative disability. Optic neuritis attacks chiefly determine visual outcome, whereas myelitis—especially cervical myelitis—more strongly affects ambulation, bladder function, and respiratory risk.[6][5] |
| Age at onset | Older age at onset, particularly onset after 50 years, is associated with faster attainment of motor-disability milestones and increased mortality risk.[9][10] |
| Delay to correct diagnosis and relapse prevention | Longer delay to correct diagnosis and effective preventive care is associated in observational cohorts with worse long-term disability, consistent with cumulative injury from preventable attacks.[9] |
| AQP4-IgG serostatus | AQP4-IgG positivity indicates persistent relapse risk. The AQP4-IgG-negative group is heterogeneous; its prognosis should not be generalized without excluding MOGAD and alternative diagnoses.[2] |
| Pregnancy and postpartum period | The postpartum period is associated with increased attack risk. Pre-pregnancy disease activity and interruption of relapse-prevention therapy are associated with greater risk of disease activity during pregnancy or postpartum.[3] |
| Comorbidity and complications | High cervical or brainstem involvement, respiratory insufficiency, severe bladder dysfunction with urosepsis, and complications of advanced immobility are associated with worse survival.[2] |
Contemporary outcome data
| Evidence source | Main finding | Interpretation and limitation |
|---|---|---|
| German NEMOS registry, 2024 | Among 298 patients with AQP4-IgG-positive NMOSD, the estimated median time from onset to an Expanded Disability Status Scale (EDSS) score of 4 was 11.9 years and to an EDSS score of 6 was 20.1 years. Older onset increased the risk of all assessed disability milestones.[9] | These are cohort estimates in a changing, predominantly treated population. EDSS emphasizes walking ability and underrepresents blindness, pain, cognition, fatigue, and other important disability domains. |
| Decade-long AQP4-IgG-positive cohort, 2026 | Among 281 patients followed for a mean of 11.3 years, PIRA occurred in 2.5%; relapse-associated worsening was far more common and occurred in 36.1% of the 194 patients who relapsed.[4] | The study reinforces that clinically meaningful disability accumulation is predominantly attack-related, while not excluding subtle subclinical injury. |
| Danish nationwide AQP4-IgG-positive cohort, 2024 | Among 66 patients, the standardized mortality ratio was 2.54 compared with the matched general population; older age at disease onset independently predicted death.[10] | The cohort was small and country-specific, so its life-expectancy estimates should not be used as universal individual predictions. |
These cohort data describe populations and must not be used as deterministic forecasts for an individual patient. Prognosis depends on attack phenotype and severity, recovery, age, comorbidities, speed of recognition, access to acute care, and effectiveness of relapse prevention.
References
- ↑ 1.0 1.1 1.2 Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189. doi:10.1212/WNL.0000000000001729. PMID: 26092914.
- ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 2.13 2.14 2.15 2.16 2.17 2.18 2.19 2.20 2.21 2.22 2.23 2.24 2.25 2.26 2.27 2.28 2.29 Jarius S, Paul F, Aktas O, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders—revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. Journal of Neurology. 2023;270(7):3341-3368. doi:10.1007/s00415-023-11634-0. PMID: 37022481.
- ↑ 3.0 3.1 3.2 3.3 3.4 Kümpfel T, Giglhuber K, Aktas O, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders—revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. Journal of Neurology. 2024;271(1):141-176. doi:10.1007/s00415-023-11910-z. PMID: 37676297.
- ↑ 4.0 4.1 4.2 Kang YR, Kim KH, Hyun JW, et al. Progression independent of relapse activity in aquaporin-4-IgG-positive NMOSD: a decade-long cohort study. Neurology: Neuroimmunology & Neuroinflammation. 2026;13(2):e200533. doi:10.1212/NXI.0000000000200533. PMID: 41435220.
- ↑ 5.0 5.1 5.2 Chen B, Francis A, Cooper SA, et al. Quantitative contribution of clinical attacks to residual disability in patients with AQP4-antibody neuromyelitis optica spectrum disorder. Neurology. 2025;104(1):e210137. doi:10.1212/WNL.0000000000210137. PMID: 39666920.
- ↑ 6.0 6.1 Palace J, Lin DY, Zeng D, et al. Outcome prediction models in AQP4-IgG-positive neuromyelitis optica spectrum disorders. Brain. 2019;142(5):1310-1323. doi:10.1093/brain/awz054. PMID: 30938427.
- ↑ 7.0 7.1 7.2 7.3 Abboud H, Salazar-Camelo A, George N, et al. Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders. Journal of Neurology. 2022;269(4):1786-1801. doi:10.1007/s00415-021-10783-4. PMID: 34482456.
- ↑ 8.0 8.1 Ayzenberg I, Richter D, Henke E, et al. Pain, depression, and quality of life in neuromyelitis optica spectrum disorder: a cross-sectional study of 166 AQP4 antibody-seropositive patients. Neurology: Neuroimmunology & Neuroinflammation. 2021;8(3):e985. doi:10.1212/NXI.0000000000000985. PMID: 34108267.
- ↑ 9.0 9.1 9.2 Duchow A, Bellmann-Strobl J, Friede T, et al. Time to disability milestones and annualized relapse rates in NMOSD and MOGAD. Annals of Neurology. 2024;95(4):720-732. doi:10.1002/ana.26858. PMID: 38086777.
- ↑ 10.0 10.1 Papp V, Magyari M, Möller S, et al. Mortality of the Danish nationwide AQP4 antibody-seropositive neuromyelitis optica spectrum disorder patient cohort. Neurology. 2024;102(5):e209147. doi:10.1212/WNL.0000000000209147. PMID: 38546185.